Apolipoprotein A-IV concentrations and cancer in a large cohort of chronic kidney disease patients: results from the GCKD study

Table 4 Association of apolipoprotein A-IV with fatal cancer during the prospective follow-up and without a history of cancer at the baseline investigation (4424 out of 5039 patients)^a

		HR	95% CI	p-value
Calculations per 10 mg/dL increment of apoA-IV concentrations
Model 1: 62 cases^b		0.60	0.43–0.85	0.003
Model 2: 60 cases^b		0.62	0.44–0.88	0.007
Calculations per quartile of ApoA-IV concentrations
Model 1	Quartile 1 (21 cases)^b	1.00
	Quartile 2 (11 cases)^b	0.42	0.20–0.87	0.02
	Quartile 3 (19 cases)^b	0.60	0.32–1.14	0.12
	Quartile 4 (11 cases)^b	0.32	0.14–0.71	0.005
Model 2	Quartile 1 (19 cases)^b	1.00
	Quartile 2 (11 cases)^b	0.46	0.22–0.98	0.04
	Quartile 3 (19 cases)^b	0.65	0.34–1.26	0.21
	Quartile 4 (11 cases)^b	0.35	0.15–0.79	0.01

Model 1: adjusted for age, sex, eGFR_cystatin-C, ln-urine albumin-creatinine ratio
Model 2: as model 1 plus statin use, smoking, BMI, diabetes
Abbreviations: HR hazard ratio, CI confidence interval
^aPatients with a history of cancer at the time of enrollment were not considered in this analysis
^b“Cases” refers to the number of patients with fatal cancer events. Differences in number of cases between model 1 and 2 are explained by few patients with some missing covariates for model 2

ISSN: 1471-2407